Typhoid Vi Polysaccharide Vaccine Global Market Report 2024

The global typhoid vi polysaccharide vaccine market has grown rapidly in recent years. It will grow from $4.98 billion in 2023 to $5.84 billion in 2024 at a compound annual growth rate (CAGR) of 17.3%. The growth observed during the historical period can be attributed to several factors, including the prevalence of diseases, global health initiatives, increased vaccination among travelers, government-led immunization campaigns, as well as the effectiveness and safety of vaccines.

The global typhoid vi polysaccharide vaccine market is expected to see rapid growth in the next few years. It will grow to $11.28 billion in 2028 at a compound annual growth rate (CAGR) of 17.9%. The anticipated growth in the forecast period can be credited to the expansion of immunization programs, a heightened focus on global health policies, improved epidemiological surveillance, increased demand for travel medicine, and various environmental and social influences. Key trends expected during this period encompass increased investments in research and development (R&D), strengthened regulatory backing, enhanced epidemiological studies, and heightened public awareness concerning public health issues.

The expansion of the typhoid Vi polysaccharide vaccine market is anticipated, driven by the increasing prevalence of typhoid. Typhoid, a potentially fatal infection caused by Salmonella typhi bacteria, is typically transmitted through contaminated food or drink. The typhoid Vi polysaccharide vaccine serves as a preventive measure, immunizing individuals aged 2 and above against typhoid fever caused by Salmonella enterica serovar Typhi (S. Typhi). In March 2021, the Centers for Disease Control and Prevention (CDC) reported an estimated 5,700 annual cases of Salmonella Typhi infections in the United States, with approximately 620 requiring hospitalization. Globally, typhoid fever is responsible for 11 to 21 million cases and 200,000 fatalities each year. Consequently, the rising prevalence of typhoid is a pivotal factor driving the growth of the typhoid Vi polysaccharide vaccine market.

The growth of immunization campaigns is poised to further fuel the expansion of the typhoid Vi polysaccharide vaccine market. Immunization campaigns, strategic initiatives conducted at national or sub-national levels, play a crucial role in rapidly reaching large populations with vaccines. Notably, the introduction of the Typhoid Conjugate Vaccine (TCV) in Nepal's routine immunization program in April 2022 exemplifies the concerted efforts to combat typhoid. This three-week campaign, supported by Gavi, the Vaccine Alliance, the World Health Organization, UNICEF, and other partners, aims to vaccinate all children aged 15 months to 15 years. With over 50,000 vaccination sites, including schools, the campaign seeks to achieve widespread protection against typhoid, enhance the impact of vaccine introduction, and address the threat of antimicrobial resistance. The increasing focus on immunization campaigns is a key driver propelling the growth of the typhoid Vi polysaccharide vaccine market.

The growth in healthcare sector expenditure is another influential factor driving the expansion of the typhoid Vi polysaccharide vaccine market. Healthcare expenditure, encompassing public and private costs, is a critical determinant of the resources available for vaccine development. In the United States, for instance, the National Health Expenditure Projections for 2018-2027 forecast healthcare expenditure to reach nearly $6.0 trillion by 2027, with an average annual growth rate of 5.5% from 2018. This upward trend in healthcare spending contributes to the development of more typhoid vaccines, consequently increasing demand for the typhoid Vi polysaccharide vaccine. The growth in healthcare sector expenditure is a pivotal factor propelling the expansion of the typhoid Vi polysaccharide vaccine market.

A prominent trend in the typhoid Vi polysaccharide vaccine market is the growing popularity of strategic partnerships, with major companies leveraging collaborations to enhance their positions in this domain. Notably, in July 2022, The International Vaccine Institute, based in South Korea and dedicated to addressing infectious diseases of global health importance, joined forces with Moderna, a leading US-based biopharmaceutical company. This strategic partnership resulted in the development of the world's first affordable oral cholera vaccine and a new-generation typhoid conjugate vaccine, showcasing the potential for collaborative efforts to drive innovation in vaccine development.

Major players in the typhoid Vi polysaccharide vaccine market are emphasizing investments to reinforce their standing in the industry. Substantial investments are being directed towards the research, development, and distribution of the typhoid Vi polysaccharide vaccine, underscoring the significance of preventing and controlling typhoid fever. A noteworthy example is the collaboration between SK Bioscience, a South Korea-based biotech company, and Vaxxas, an Australia-based biotechnology company specializing in needle-free vaccination technology. In August 2023, this partnership secured AUD5.4 million ($3.67 million) in funding from Wellcome, a UK-based charity. The funding aims to support the development of a typhoid conjugate vaccine that can be delivered through a needle-free patch, reflecting a commitment to innovative vaccine delivery methods. This collaboration brings together Vaxxas' high-density microarray patch (HD-MAP) platform technology with SK Bioscience's proprietary typhoid vaccine, presenting a potential breakthrough in vaccine delivery mechanisms.

Major companies operating in the typhoid vi polysaccharide vaccine market report are Sanofi Pasteur SA, GlaxoSmithKline PLC, Merck & Co. Inc., Pfizer Inc., Johnson & Johnson Private Limited, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Emergent Biosolutions Inc., PT Bio Farma, Bharat Biotech International Limited, Teva Pharmaceutical Industries Ltd., Novartis AG, Mylan NV, Serum Institute of India Pvt. Ltd., Biological E. Limited, Panacea Biotec Ltd., Shantha Biotechnics Pvt. Ltd., Cadila Healthcare Ltd., Merck Sharp & Dohme Corp., AstraZeneca Limited, Boryung Pharmaceutical Co., Bio-Med Pvt. Ltd., LG Chem, SK Chemicals Co. Ltd., Crucell Switzerland AG, Hualan Biological Engineering Inc., Indian Immunologicals Limited

Asia-Pacific was the largest region in the typhoid Vi polysaccharide vaccine market share in 2023. The regions covered in the typhoid vi polysaccharide vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the typhoid vi polysaccharide vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary variants of this vaccine are tailored for pediatric and adult use. A child denotes an individual from birth to puberty or reaching full physical maturity. The vaccine can be administered orally or through parenteral routes and is accessible across governmental, private, and other institutional healthcare settings.

This report provides typhoid Vi polysaccharide vaccine market statistics, including typhoid Vi polysaccharide vaccine industry global market size, regional shares, competitors with typhoid Vi polysaccharide vaccine market share, detailed typhoid Vi polysaccharide vaccine market segments, market trends and opportunities, and any further data you may need to thrive in typhoid Vi polysaccharide vaccine industry. This Typhoid Vi polysaccharide vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The typhoid Vi polysaccharide vaccine market consists of sales of Vi capsular polysaccharide vaccine, and non-conjugated Vi polysaccharide vaccine. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.